CAMP4 Therapeutics Corporation (NASDAQ:CAMP) Given Consensus Recommendation of “Moderate Buy” by Analysts

CAMP4 Therapeutics Corporation (NASDAQ:CAMP) has been given a consensus recommendation of “Moderate Buy” by the nine brokerages that are currently covering the stock, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation and seven have given a buy recommendation to the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $8.3571.

Several research analysts have issued reports on the company. Chardan Capital set a $6.50 target price on CAMP4 Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, June 10th. Weiss Ratings cut shares of CAMP4 Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, May 21st. JPMorgan Chase & Co. raised shares of CAMP4 Therapeutics from a “neutral” rating to an “overweight” rating and raised their price objective for the stock from $5.00 to $9.00 in a report on Tuesday, June 16th. Zacks Research cut shares of CAMP4 Therapeutics from a “hold” rating to a “strong sell” rating in a report on Wednesday, July 15th. Finally, Rodman & Renshaw began coverage on shares of CAMP4 Therapeutics in a research report on Tuesday, April 14th. They issued a “buy” rating and a $7.00 price target on the stock.

CAMP4 Therapeutics Price Performance

Shares of CAMP opened at $4.22 on Tuesday. CAMP4 Therapeutics has a one year low of $1.32 and a one year high of $7.75. The firm has a market capitalization of $219.14 million, a P/E ratio of -1.79 and a beta of 0.22. The business has a fifty day moving average of $4.02 and a 200 day moving average of $4.29.

Insider Buying and Selling

In related news, Director Richard A. Young bought 16,378 shares of the stock in a transaction that occurred on Monday, August 3rd. The shares were bought at an average cost of $1.65 per share, for a total transaction of $27,023.70. Following the completion of the transaction, the director owned 186,388 shares of the company’s stock, valued at approximately $307,540.20. This trade represents a 9.63% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last quarter, insiders acquired 36,031 shares of company stock valued at $59,451. 21.69% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in CAMP. SummitTX Capital L.P. purchased a new position in shares of CAMP4 Therapeutics during the 1st quarter valued at about $1,497,000. EcoR1 Capital LLC bought a new stake in CAMP4 Therapeutics during the 4th quarter worth approximately $1,992,000. Jefferies Financial Group Inc. bought a new stake in CAMP4 Therapeutics during the 4th quarter worth approximately $70,000. China Universal Asset Management Co. Ltd. purchased a new position in CAMP4 Therapeutics during the fourth quarter valued at approximately $61,000. Finally, Jane Street Group LLC purchased a new position in CAMP4 Therapeutics during the fourth quarter valued at approximately $157,000.

About CAMP4 Therapeutics

CalAmp Corp., a connected intelligence company, provides leverages a data-driven solutions ecosystem to people and organizations in the United States, Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and internationally. The company operates in two segments, Software & Subscription Services and Telematics Products. It provides CalAmp Telematics Cloud platform, such as cloud-based application enablement and telematics service platforms that facilitate integration of its own applications, as well as those of third parties, through open application programming interfaces; and software as a service application, as well as provides tracking and monitoring services within fleet management, supply chain integrity, and international vehicle location.